Howard Levin
Principal investigator, leads Axon Therapies Inc..
MedtechFounder
Built from public records only: federal awards, patents, filings and papers.Is this you? Contact Noair Lab to claim this profile, correct it or hide it.
2016First federal award
$11.9MFederal grants as PI19 awards
0Patents grantedNone matched
0PapersOpenAlex
Federal awards and patents by year
AwardsPatents
19 awards · $11.9M
| Date | Agency | Award | Amount | Company |
|---|---|---|---|---|
| Sep 1, 2026 | NIH | SBIR Phase I Cooled RF Bronchoscopic Lung Volume Reduction | $305K | Coridea, LLC |
| Aug 6, 2026 | NIH | SBIR Phase I Percutaneous Stellate Ganglion Stimulation in Septic Shock to Improve Hemodynamics and Vasopressor Requirements During Transport | $294K | Coridea, LLC |
| Jun 5, 2024 | NIH | SBIR Phase I Stellate Ganglion Stimulation in Septic Shock to Improve Hemodynamics and Vasopressor Requirements | $275K | Coridea, LLC |
| Apr 22, 2024 | NIH | SBIR Phase II Minimally Invasive High Intensity Therapeutic Ultrasound for the Treatment of Obstructive Hypertrophic Cardiomyopathy | $123K | Coridea, LLC |
| Apr 19, 2024 | NIH | SBIR Phase II Minimally Invasive High Intensity Therapeutic Ultrasound for the Treatment of Obstructive Hypertrophic Cardiomyopathy | $942K | Coridea, LLC |
| Aug 11, 2023 | NIH | SBIR Phase II Minimally Invasive High Intensity Therapeutic Ultrasound for the Treatment of Obstructive Hypertrophic Cardiomyopathy | $123K | Coridea, LLC |
| Apr 30, 2023 | NIH | SBIR Phase II Minimally Invasive High Intensity Therapeutic Ultrasound for the Treatment of Obstructive Hypertrophic Cardiomyopathy | $785K | Coridea, LLC |
| Aug 18, 2022 | NIH | SBIR Phase II Novel Minimally Invasive Endobronchial Approach for Lung Cancer Ablation | $784K | Coridea, LLC |
| Apr 13, 2022 | NIH | SBIR Phase I Coridea NIH I-Corps Program | $55K | Coridea, LLC |
| Sep 24, 2021 | NIH | SBIR Phase II Novel Minimally Invasive Endobronchial Approach for Lung Cancer Ablation | $1.6M | Coridea, LLC |
| Sep 22, 2021 | NIH | SBIR Phase I On Demand Electrostimulation | $224K | Coridea, LLC |
| May 2, 2020 | NIH | SBIR Phase II Painless Defibrillation | $983K | Coridea, LLC |
| Apr 24, 2019 | NIH | SBIR Phase II Painless Defibrillation | $994K | Coridea, LLC |
| Apr 1, 2019 | NIH | SBIR Phase I Novel Minimally Invasive Endobronchial Approach for Lung Cancer Ablation | $225K | Coridea, LLC |
| May 10, 2018 | NIH | SBIR Phase II Painless Defibrillation | $994K | Coridea, LLC |
| Mar 15, 2018 | NIH | SBIR Phase II Minimally Invasive Cardiac Sympathetic Denervation for Malignant Ventricular Arrhythmia | $1.5M | Coridea, LLC |
| Mar 1, 2018 | NIH | SBIR Phase I Automatic Phrenic Nerve Stimulation to Rescue Opioid Induced Respiratory Depression | $225K | Coridea, LLC |
| Jun 30, 2017 | NIH | SBIR Phase II Prevention of Syncope with GSN Stimulation | $726K | Coridea, LLC |
| Sep 8, 2016 | NIH | SBIR Phase II Prevention of Syncope with GSN Stimulation | $740K | Coridea, LLC |
Peer ranks
Federal funding#50
Awards as PI#32
Patents#505
Companies
- Axon Therapies Inc.Leads (SEC Form D) · Medtech
- Coridea, LLCLinked by awards · Medtech
Federal awards through Oct 21, 2026 and patents through Oct 20, 2026. Awards come from NIH, NSF and other agency records that name a principal investigator; DoD and NASA contract awards do not, so they are not shown here. Researchers are matched by name and company.